$ABBV · AbbVie Inc. SEC Filings
Position Tracker tracks 10 SEC EDGAR filings for AbbVie Inc. ($ABBV) from August 18, 2026 through November 3, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 5 Form 8-K current event disclosures, and 4 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$ABBV 10-Q — AbbVie Inc.
AbbVie's immunology duo Skyrizi and Rinvoq now generate $8.48B quarterly, proving the Humira patent-cliff transition is complete — but the balance sheet carries $80.9B in total…
$ABBV 8-K — AbbVie Inc.
AbbVie Inc. filed a current report on Form 8-K disclosing that Jennifer L. Davis, a Class II director, notified the company’s board of directors on October 28, 2026, of her inte…
$ABBV 8-K — AbbVie Inc.
AbbVie's immunology portfolio is firing on all cylinders — Skyrizi and Rinvoq combined for $8.48B in quarterly revenue — while the Apogee acquisition and pipeline readouts exten…
$ABBV 3 — AbbVie Inc.
AbbVie Inc. filed a Form 3 with the SEC on October 23, 2026, for John Carethers. The form is an initial statement of beneficial ownership required under Section 16(a) of the Sec…
$ABBV 8-K — AbbVie Inc.
AbbVie Inc. filed a current report on Form 8-K dated October 14, 2026, disclosing a change to its board of directors. The company expanded the size of its board from twelve to t…
$ABBV 8-K — AbbVie Inc.
AbbVie Inc. filed a current report on Form 8-K on October 5, 2026, to update its earnings guidance for acquired in-process research and development, or IPR&D, and milestone expe…
$ABBV 4 — AbbVie Inc.
AbbVie Inc. filed a Form 4 with the SEC reporting a change in beneficial ownership for Susan E. Quaggin, a member of the company’s board of directors. The filing shows that on S…
$ABBV 4 — AbbVie Inc.
AbbVie Inc. filed a Form 4 with the SEC on October 2, 2026, reporting a change in beneficial ownership for Edward J. Rapp, a director of the company. The filing shows that on Se…
$ABBV 8-K — AbbVie Inc.
AbbVie Inc. filed a current report on Form 8-K dated September 3, 2026, announcing that it had completed its acquisition of Apogee Therapeutics, Inc. The company issued a press…
$ABBV 4 — AbbVie Inc.
This SEC Form 4 filing discloses transactions by Nicholas Donoghoe, AbbVie’s Executive Vice President and Chief Business/Strategy Officer. On August 14, 2026, he exercised emplo…